Altimmune (ALT) Other Operating Expenses (2010 - 2023)

Altimmune's (ALT) quarterly Other Operating Expenses came in at $12.4 million in Q4 2023, up 276.33% on a QoQ basis from $3.3 million in Q4 2021.

Altimmune (ALT) Other Operating Expenses (2010 - 2023) Analysis & Trends

Altimmune (ALT) has 12 years of Other Operating Expenses data on file, last reported at $12.4 million in Q4 2023.

On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $12.4 million in Q4 2023; TTM through Sep 2024 was $12.4 million, a N/A change from a year earlier, with the FY2023 full-year figure at $12.4 million, changed N/A from the prior year.
Other Operating Expenses for Q4 2023 stood at $12.4 million, up from $3.3 million in the prior quarter.
Over the last five years, Other Operating Expenses for ALT reached as high as $12.4 million in Q4 2023 and fell as low as $1.0 million in Q3 2019.
Historically, Other Operating Expenses has averaged $6.2 million across 3 years, with a median of $5.7 million in 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Altimmune	346.63 Mn	346.63 Mn	-

Download Data